Gene · 8438
RAD54L: RAD54 like
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RAD54L: RAD54 like. Genes, record 8438. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8438
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q92698 | DNA repair and recombination protein RAD54-like | 747 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents33
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 9305 | Q92698 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5533 | Q92698 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9305 | Q92698 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5533 | Q92698 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8045 | Q92698 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8046 | Q92698 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 196 | Q92698 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 71189 | Q92698 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 71190 | Q92698 | Espacenet |
| JP 2022092366 A | 2022-06-22 | 803 | Q92698 | Espacenet |
1 to 10 of 33
See all 33 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,244
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RAD54L papers | Newest fiscal year |
|---|---|---|---|
| R01GM058015 | Recombinational Mechanisms of DNA Repair | 26 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 22 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 19 | 2025 |
| R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 17 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 16 | 2025 |
| R35GM118026 | Mechanisms of Genome Integrity | 11 | 2025 |
| ZIAAG000741 | Roles Of DNA Helicases In Pathways Required For Maintenance Of Genomic Stability | 10 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 9 | 2025 |
| P30CA056036 | Translational Research in Cancer | 8 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 7 | 2025 |
1 to 10 of 1,244Source NIH's project files
See all 1,244 nih grantsPapers1,865
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MCPH1 and DNA Damage Response Pathway Genes as Candidate Susceptibility Loci in Hereditary Breast Cancer. | Diagnostics (Basel) | 2026 | 42793752 | PubTator, text mining | PubMed |
| Whole-genome sequencing identifies a potentially causative homozygous splicing variant in RAD54 like in non-obstructive azoospermia. | Int J Reprod Biomed | 2026 | 42774555 | PubTator, text mining | PubMed |
| The dynamics of RAD51 foci formation and elongation in living human cells. | Nucleic Acids Res | 2026 | 42725434 | PubTator, text mining | PubMed |
| RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability. | EMBO J | 2026 | 42493648 | PubTator, text mining | PubMed |
| Role of chromatin remodeling and immunopharmacology in cancer therapy. | Mol Med | 2026 | 42458295 | PubTator, text mining | PubMed |
| Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States. | Urol Oncol | 2026 | 42431822 | PubTator, text mining | PubMed |
| NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis. | Respir Res | 2026 | 42399962 | PubTator, text mining | PubMed |
| FBH1 and RAD54L directly interact and cooperate to drive replication fork reversal. | bioRxiv | 2026 | 42239417 | PubTator, text mining | PubMed |
| Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer. | Sci Rep | 2026 | 42215586 | PubTator, text mining | PubMed |
| RAD54L promotes nascent DNA degradation and radial chromosome formation in FANC-deficient cells. | bioRxiv | 2026 | 42182380 | PubTator, text mining | PubMed |
1 to 10 of 1,865
See all 1,865 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8438
GET https://conductscience.org/api/genes/v1/8438/patents?page=2